Here we evaluated LV-mediated gene delivery of engineered versions of FVIII transgene in hemophilia A mice and in NHP, showing long-term FVIII activity and restoration of hemostasis, following i.v. administration to newborn and adult mice and normal-range human FVIII activity in NHP. The gene discussed is F8; the disease is hemophilia.